Biotech Values

[dewophile]

inf lambda vs all inf alphas

i agree with clark - lambda is unique in its SE profile. the tolerability of lambda alone would enable it to dominate the entire INF market regardless of how many alpha interferon follow-ons there are (including those with improved dosing schedules and perhaps slightly better tolerability like locteron)

a big eye opener - docs in trials said relapsers who got study drug thought they were in the placebo arm. that to me spoke volumes on tolerability of lambda and why no other INF could touch it in a competitive environment (its also why the large phase 2 enrolled so quickly)